Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,399 result(s) found. Displaying page 2,025 of 2,220.
    «« First « Previous 2021  2022  2023  2024  2025  2026  2027  2028  2029  Next» Last»»
    EudraCT Number: 2018-000743-66 Sponsor Protocol Number: NAMCHEM Start Date*: 2018-07-10
    Sponsor Name:FONDAZIONE LUIGI MARIA MONTI IDI-IRCCS
    Full Title: Multicenter, interventional, single-arm, phase IV study on specific metabolic and genomic profiles as predictors of nicotinamide efficacy in cutaneous squamous cell carcinoma prevention
    Medical condition: Cutaneous squamous-cell carcinoma (cSCC) is the most common age-associated malignancy that usually arises from the lesion actinic keratosis (AK) or grows de novo in photoexposed areas.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059813 Spinocellular carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003250-23 Sponsor Protocol Number: 78162.018.21 Start Date*: 2025-01-24
    Sponsor Name:Amsterdam UMC
    Full Title: Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X Syndrome: an N-of-1 series
    Medical condition: Tuberous Sclerosis Complex (TSC), Sanfilippo syndrome, Fragile X syndrome (FXS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    20.0 10010331 - Congenital, familial and genetic disorders 10027424 Metabolic and nutritional disorders congenital HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001836-24 Sponsor Protocol Number: CCFZ533A2202 Start Date*: 2019-05-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-month, open-label, multicenter, randomized, safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) study of two regimens of anti-CD40 monoclonal antibody, CFZ533 vs. standard of care ...
    Medical condition: Liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10024715 Liver transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) HU (Prematurely Ended) FR (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000421-31 Sponsor Protocol Number: Etelcalcetide-T50-CKD5D-2018 Start Date*: 2018-12-19
    Sponsor Name:Ordensklinikum Linz GmbH, ELISABETHINEN, Interne 3
    Full Title: A study to investigate the influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients
    Medical condition: End stage renal disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004336-16 Sponsor Protocol Number: CC-93538-EE-001 Start Date*: 2021-09-29
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 3, Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subject...
    Medical condition: EOSINOPHILIC ESOPHAGITIS
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PT (Completed) BE (Completed) PL (Completed) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-004789-24 Sponsor Protocol Number: PA21-T50-CKD5D-2016 Start Date*: 2017-03-10
    Sponsor Name:Ordensklinikum Linz, Krankenhaus der Elisabethinen Linz GmbH, III. Interne
    Full Title: The Effect of Phosphate Lowering using sucroferric oxyhydroxide (PA21) on Calcification Propensity of Serum – a randomized, controlled, open-label, cross-over trial
    Medical condition: end stage renal disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000813-37 Sponsor Protocol Number: OCABSGS Start Date*: 2012-05-16
    Sponsor Name:Sahlgrenska Academy
    Full Title: Effects of obeticholic acid on hepatic fatty acid/triglyceride metabolism and hepatobiliary detoxification/elimination in morbidly obese and gallstone patients.
    Medical condition: Fatty liver disease, morbid obesity, gallstone disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002162-40 Sponsor Protocol Number: 2021-004 Start Date*: 2022-02-21
    Sponsor Name:Haaglanden Medisch Centrum
    Full Title: IBIS: A single-centre, phase II study to evaluate the safety, tolerability and pharmacokinetics of 2-IminoBiotin in acute Ischemic Stroke due to large vessel occlusion
    Medical condition: Acute ischemic stroke due to proximal large vessel occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003242-20 Sponsor Protocol Number: p135 Start Date*: 2023-03-09
    Sponsor Name:Maastricht University
    Full Title: Effects of recreational nitrous oxide use on psychomotor functioning related to driving performance
    Medical condition: The impairing effects of recreational nitrous oxide use on psychomotor functioning related to driving performance and its relation to detected concentration in exhaled air
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001686-40 Sponsor Protocol Number: A01811 Start Date*: 2011-09-15
    Sponsor Name:German Heart Centre Munich, Department of Cardiovascular Diseases
    Full Title: INTRACORONARY STENTING AND ANTITHROMBOTIC REGIMEN: ADJUSTING ANTIPLATELET TREATMENT IN PATIENTS BASED ON PLATELET FUNCTION TESTING - ISAR ADAPT-PF
    Medical condition: Effect of Ticagrelor and Prasugrel in patients with insufficient responding to Clopidogrel after coronary intervention (non-inferiority of Ticagrelor vs. Prasugrel)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001890-27 Sponsor Protocol Number: D4200C00079 Start Date*: 2007-06-15
    Sponsor Name:AstraZeneca SAS
    Full Title: A Randomized, Double Blind, placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima™ in Patients with advanced or metastatic papillary or follicular Thyroid Car...
    Medical condition: Advanced or metastatic papillary or follicular Thyroid Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001205 Adenocarcinoma thyroid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DK (Completed) SE (Completed) ES (Ongoing) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000494-20 Sponsor Protocol Number: ABC-SE Start Date*: 2016-07-03
    Sponsor Name:Skåne University Hospital, Department of Oncology
    Full Title: A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Based Treatment with Focus on Mechanisms of Resistance to Endocrine Based Treatment (fulvestrant/aroma...
    Medical condition: Estrogen receptor positive metastatic or locally advanced inoperable breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012041-35 Sponsor Protocol Number: TNF-K-003 Start Date*: 2010-07-02
    Sponsor Name:Neovacs SA
    Full Title: A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthrit...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Ongoing) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001476-37 Sponsor Protocol Number: PENTA17 Start Date*: 2015-12-16
    Sponsor Name:Fondazione PENTA ONLUS
    Full Title: SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety ...
    Medical condition: Paediatric HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002185-40 Sponsor Protocol Number: LSH-21-001 Start Date*: 2022-10-06
    Sponsor Name:Landspitali - The National University Hospital of Iceland
    Full Title: Comparison of the Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion and Plasma Levels in Patients with Adenine Phosphoribosyltransferase Deficiency: A Clinical Trial
    Medical condition: Adenine phosphoribosyltransferase deficiency
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004248-49 Sponsor Protocol Number: NL69508.058.19 Start Date*: 2020-02-26
    Sponsor Name:Leiden University Medical Center
    Full Title: Phase 1b/2 Study Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced Uveal Melanoma (CHOPIN)
    Medical condition: Metastatic uveal melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000140-58 Sponsor Protocol Number: NL7255100000 Start Date*: 2020-07-23
    Sponsor Name:Leiden University Medical Center
    Full Title: Complement Inhibition: Attacking the Overshooting Inflammation @fter Traumatic Brain Injury - A phase II trial on the safety and efficacy of C1 esterase inhibitor Cinryze for the acute management o...
    Medical condition: Severe traumatic Brain Injury (TBI) with GCS < 13
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10060690 Traumatic brain injury LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002944-10 Sponsor Protocol Number: c16174 Start Date*: 2019-02-27
    Sponsor Name:Memorial Sloan Kettering Cancer Center
    Full Title: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Medical condition: Patients with histological or cytological proof of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003787-48 Sponsor Protocol Number: BP41674 Start Date*: 2020-06-11
    Sponsor Name:F. Hoffmann-La Roche
    Full Title: AN OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7248824 IN PARTICIPANTS WITH ANGELMAN SYNDROME
    Medical condition: Angelman Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049004 Angelman's syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004032-28 Sponsor Protocol Number: 112415 Start Date*: 2021-11-24
    Sponsor Name:Radboud University Medical Center
    Full Title: Pharmacokinetic boosting of olaparib to improve exposure, tolerance and cost-effectiveness (PROACTIVE-study)
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2021  2022  2023  2024  2025  2026  2027  2028  2029  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 12 03:13:29 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA